Senti Cash Flow To Debt Ratio from 2010 to 2024
| SNTI Stock | USD 2.17 0.05 2.36% |
Cash Flow To Debt Ratio | First Reported 2010-12-31 | Previous Quarter (15.80) | Current Value (16.59) | Quarterly Volatility 0.50072142 |
Check Senti Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Senti Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.2 M, Interest Expense of 4.7 M or Selling General Administrative of 25.5 M, as well as many indicators such as Price To Sales Ratio of 10.86, Dividend Yield of 0.0 or PTB Ratio of 0.42. Senti financial statements analysis is a perfect complement when working with Senti Biosciences Valuation or Volatility modules.
Senti | Cash Flow To Debt Ratio |
Currently Active Assets on Macroaxis
When determining whether Senti Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Senti Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Senti Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Senti Biosciences Stock:Check out the analysis of Senti Biosciences Correlation against competitors. For more detail on how to invest in Senti Stock please use our How to Invest in Senti Biosciences guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Senti Biosciences. If investors know Senti will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Senti Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (15.59) | Revenue Per Share 0.075 | Quarterly Revenue Growth (1.00) | Return On Assets (0.33) | Return On Equity (1.11) |
The market value of Senti Biosciences is measured differently than its book value, which is the value of Senti that is recorded on the company's balance sheet. Investors also form their own opinion of Senti Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Senti Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Senti Biosciences' market value can be influenced by many factors that don't directly affect Senti Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Senti Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Senti Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Senti Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.